Vita Life Sciences Ltd - Asset Resilience Ratio
Vita Life Sciences Ltd (VLS) has an Asset Resilience Ratio of 39.38% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Vita Life Sciences Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Vita Life Sciences Ltd's Asset Resilience Ratio has changed over time. See VLS total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vita Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Vita Life Sciences Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$29.40 Million | 39.38% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$29.40 Million | 39.38% |
Asset Resilience Insights
- Very High Liquidity: Vita Life Sciences Ltd maintains exceptional liquid asset reserves at 39.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Vita Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Vita Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277 |
Drug Manufacturers - Specialty & Generic | 31.63% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 3.29% |
Annual Asset Resilience Ratio for Vita Life Sciences Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Vita Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.90% | AU$21.50 Million ≈ $15.21 Million |
AU$71.89 Million ≈ $50.87 Million |
-2.21pp |
| 2023-12-31 | 32.11% | AU$19.20 Million ≈ $13.59 Million |
AU$59.81 Million ≈ $42.32 Million |
+24.68pp |
| 2022-12-31 | 7.42% | AU$3.85 Million ≈ $2.72 Million |
AU$51.80 Million ≈ $36.65 Million |
-5.81pp |
| 2021-12-31 | 13.23% | AU$5.99 Million ≈ $4.24 Million |
AU$45.27 Million ≈ $32.03 Million |
+2.03pp |
| 2020-12-31 | 11.21% | AU$4.38 Million ≈ $3.10 Million |
AU$39.10 Million ≈ $27.67 Million |
+5.43pp |
| 2019-12-31 | 5.77% | AU$2.11 Million ≈ $1.49 Million |
AU$36.51 Million ≈ $25.84 Million |
-24.86pp |
| 2018-12-31 | 30.63% | AU$10.94 Million ≈ $7.74 Million |
AU$35.72 Million ≈ $25.27 Million |
+17.52pp |
| 2017-12-31 | 13.11% | AU$4.32 Million ≈ $3.06 Million |
AU$32.95 Million ≈ $23.32 Million |
+7.82pp |
| 2016-12-31 | 5.30% | AU$1.71 Million ≈ $1.21 Million |
AU$32.36 Million ≈ $22.90 Million |
+0.24pp |
| 2015-12-31 | 5.05% | AU$1.64 Million ≈ $1.16 Million |
AU$32.39 Million ≈ $22.92 Million |
-- |
About Vita Life Sciences Ltd
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods. It markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands… Read more